What the Study Found (In Plain English)
Published in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025), this phase iii randomized trial evaluating 52 human participants investigated: Custodiol is a well-established preservation solution for organ transplantation and was the basis for the development of Custodiol-N to improve graft preservation. Key clinical takeaway: This study shows that Custodiol-N is safe, noninferior, and provides similar cardiac graft protection as the established Custodiol solution.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2025-08-15; N = 52; Rigor 82/100): This study shows that Custodiol-N is safe, noninferior, and provides similar cardiac graft protection as the established Custodiol solution.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.